Does Anticholinergic Activity Affect Neuropathology? Implication of Neuroinflammation in XXXX .

@entity1 @entity13859 @entity303 @entity19 @entity179 @entity195 @entity8124 @entity528
One characteristic neuropathological feature of @entity195 ( @entity195 ) is profound @entity528 in the nucleus basalis of Meynert, the major source of cholinergic innervation of the cerebral cortex. Clinically, anticholinergic activity causes a decline in cognitive function and increases the risk of @entity303 , thus possibly enhancing @entity195 pathologies and @entity179 . Until now there has been insufficient @entity1 neuropathological data to support this conclusion. Experimental studies using a @entity13859 @entity19 model demonstrated anticholinergics enhanced tau pathology and @entity179 corresponding to central anticholinergic activity. Additionally, @entity8124 , a cholinesterase inhibitor, ameliorated tau pathology and @entity179 in the same @entity19 model. These results indicate the balance between cholinergic and anticholinergic activities might affect @entity179 . Importantly, @entity179 observed in the @entity19 model seemed to correspond to the distribution of microglial activation, and it was reported that neuroinflammation plays an important role in the pathomechanism of @entity195 , while anticholinergic activity augments inflammatory responses. Moreover, some studies indicated b-amyloid itself depletes cholinergic function similarly to anticholinergic activity. Thus, anticholinergic activity might initiate and/or accelerate @entity195 pathology. Limited @entity1 data support the conclusion that anticholinergic activity enhances @entity195 -related neuropathology and @entity179 . However, experimental data from a @entity13859 @entity19 model indicated anticholinergic activity might enhance @entity179 with enhanced neuroinflammation including microglial activation.
